Company intelligence / Profile preview
Etcembly
Harwell, Oxfordshire, United Kingdometcembly.io ↗
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
01
Overview
Successfully developed ETC-101, a bispecific T cell engager targeting PRAME with picomolar affinity. The lead drug binds to PRAME with a million-fold greater affinity than a natural TCR without binding to healthy tissue cells, suggesting high potency with few side effects[4][7].
- Therapeutic areas
- OncologyImmunology
- Modalities
- T Cell Receptors (TCRs)AntibodiesBispecificsVHHsT cell engagers
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Vector LaboratoriesIlluminaGreat Ormond Street HospitalZelluna ASSingHealthNational Cancer Centre SingaporeImperial College LondonUniversity of Surrey
Beyond the preview
Go deeper on Etcembly.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Etcembly.